Muscle & Brawn 2.0 is live! New Tools, Voice Reader, Compound Index, Features and more on the way. Want to explore what’s new → Click Here
Independent & reader-supported — every article medically reviewed

Cycle support / SERMs

14 In the index

Raloxifene RALOX

An FDA-approved medication (Evista) that helps prevent and treat osteoporosis and lowers breast cancer risk in postmenopausal women. Large human studies strongly support both uses, with a higher risk of blood clots being the main safety concern.

Also known as Evista, Keoxifene, Raloxifeno, Raloxifenum, Raloxifenum [Latin], Raloxiphene, Eviden, Raxeto

Effects Hormonal
Routes Oral
Legal status Prescription drug
WADA Banned at all times

3D Molecular Structure of C28H27NO4S

Drag to rotate · scroll to zoom

  • Carbon
  • Hydrogen
  • Nitrogen
  • Oxygen
  • Sulfur

Chemistry

Formula
C28H27NO4S
Molar mass
473.6
CAS
84449-90-1
PubChem CID
5035
IUPAC name
[6-hydroxy-2-(4-hydroxyphenyl)-1-benzothiophen-3-yl]-[4-(2-piperidin-1-ylethoxy)phenyl]methanone
InChIKey
GZUITABIAKMVPG-UHFFFAOYSA-N

Reported dosing

User-reported

What has been reported in the literature and by users. This is a record of what is done, not a recommendation.

Typical dose 60 mg/day
Reported range 60 mg/day (standard); off-label bodybuilding use sometimes intermittent
Route Oral
Frequency Once daily
Duration Chronic (as prescribed) or cycle-length (off-label bodybuilding use)

FDA-approved SERM (Evista) for osteoporosis and breast cancer risk reduction; used off-label by some steroid users for estrogen management, particularly to address gynecomastia.

Where this comes from FDA prescribing information; off-label user-reported dosing

There is no approved human dosing for this compound. The figures above are what users and vendors report, not what has been established as safe or effective. Treat them as a record of what is done, not as guidance.